Bcl-xL Activators
Bcl-xL activators are a class of chemical compounds that specifically interact with the Bcl-xL protein, a member of the B-cell lymphoma 2 (Bcl-2) family of proteins. These proteins are crucial in regulating apoptosis, which is the process of programmed cell death. Bcl-xL activators are designed to modulate the activity of Bcl-xL, resulting in the manipulation of its normal cellular functions. The Bcl-xL protein itself plays a role in maintaining the balance between cell survival and cell death by controlling the permeability of the mitochondrial membrane to apoptotic factors. Bcl-xL activators, through their interaction with the protein, can affect this balance by altering Bcl-xL's conformation or its ability to bind to other molecules within the cell. The activators can either be naturally occurring substances or synthetic molecules created through chemical synthesis, and their structures are often complex, reflecting the intricate nature of the protein surfaces they are meant to interact with.
The development and study of Bcl-xL activators involve a deep understanding of protein chemistry and structure-activity relationships. These compounds must be carefully crafted to ensure specificity for the Bcl-xL protein, as the Bcl-2 family contains several closely related proteins with similar structures and functions. The specificity is vital to ensure that the activators interact predominantly with Bcl-xL and not other unintended cellular targets. Researchers utilize a variety of techniques, including X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and molecular docking simulations, to study the interaction between Bcl-xL and potential activators.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ABT 737 | 852808-04-9 | sc-207242 | 2.5 mg | $200.00 | 54 | |
ABT-737 is a small molecule inhibitor that mimics the BH3 domain of Bim and binds to Bcl-xL, preventing its anti-apoptotic function. This interaction promotes apoptosis by disrupting the protective role of Bcl-xL, allowing pro-apoptotic signals to proceed. While ABT-737 is often classified as an inhibitor, its mechanism involves interfering with Bcl-xL's anti-apoptotic activity, ultimately promoting apoptotic processes. | ||||||
TW-37 | 877877-35-5 | sc-361387 sc-361387A | 10 mg 50 mg | $200.00 $860.00 | 2 | |
TW-37 is a small molecule that targets Bcl-2 family proteins, including Bcl-xL, and induces apoptosis. While typically characterized as an inhibitor, its mechanism involves disrupting the anti-apoptotic function of Bcl-xL, leading to the activation of apoptosis. Thus, TW-37 can be regarded as an indirect activator of apoptotic pathways by antagonizing the protective role of Bcl-xL. | ||||||
Sabutoclax | 1228108-65-3 | sc-472977 | 1 mg | $330.00 | ||
Sabutoclax is a pan-Bcl-2 family inhibitor that targets anti-apoptotic proteins, including Bcl-xL. Despite its classification as an inhibitor, its impact on Bcl-xL involves neutralizing its anti-apoptotic function, leading to the activation of apoptotic pathways. Therefore, Sabutoclax serves as an indirect activator of apoptosis by antagonizing the protective role of Bcl-xL against pro-apoptotic signals. | ||||||
Gossypol | 303-45-7 | sc-200501 sc-200501A | 25 mg 100 mg | $114.00 $225.00 | 12 | |
Gossypol is a natural compound that inhibits Bcl-xL and other anti-apoptotic proteins. Despite its classification as an inhibitor, its mechanism involves neutralizing the anti-apoptotic function of Bcl-xL, leading to the activation of apoptotic pathways. Consequently, Gossypol functions as an indirect activator of apoptosis by antagonizing the protective role of Bcl-xL against pro-apoptotic signals. | ||||||
S63845 | 1799633-27-4 | sc-507518 | 1 mg | $150.00 | ||
S63845 is a selective Bcl-xL inhibitor that binds to the BH3 binding groove, promoting apoptosis by disrupting the protective function of Bcl-xL. While commonly referred to as an inhibitor, its mechanism involves inhibiting the anti-apoptotic activity of Bcl-xL, leading to the activation of apoptotic pathways. Therefore, S63845 can be considered an indirect activator of apoptosis by targeting and neutralizing Bcl-xL. | ||||||